Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

BAVARIAN NORDIC

BAVA.CODK0015998017NASDAQ CopenhagenDKDKK
Stock price
BAVARIAN NORDIC
Loading chart...

Coverage

Latest articles

Bavarian Nordic chair resigns after failed takeover bid
14 Nov 2025, 06:43BAVA.CONASDAQ Copenhagen

Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker said, days after a takeover bid from a private equity consortium collapsed.

Bavarian Nordic chair resigns after failed takeover bid
13 Nov 2025, 19:48BAVA.CONASDAQ Copenhagen

Bavarian Nordic's Chair of the Board, Luc Debruyne, has resigned with immediate effect, the Danish vaccine maker announced Thursday, days after a private equity takeover bid for the company collapsed.

Bavarian Nordic shareholders reject private equity takeover bid
6 Nov 2025, 14:06BAVA.CONASDAQ Copenhagen

A takeover offer for Danish vaccine maker Bavarian Nordic from a private equity consortium led by Nordic Capital and Permira has been withdrawn after failing to gain sufficient shareholder support.

Bavarian Nordic deal struggles as vaccine contract boosts value
31 Oct 2025, 13:13BAVA.CONASDAQ Copenhagen

A private equity consortium's takeover bid for Danish vaccine maker Bavarian Nordic is facing a crucial deadline, complicated by a major new European vaccine contract that could bolster the company's standalone value.

New EU vaccine deal complicates Bavarian Nordic takeover
31 Oct 2025, 08:21BAVA.CONASDAQ Copenhagen

Bavarian Nordic has secured a new long-term contract to supply the European Union with up to 8 million doses of its smallpox and mpox vaccine over the next four years, the company said Friday.

Private equity lowers Bavarian Nordic takeover threshold
21 Oct 2025, 12:48BAVA.CONASDAQ Copenhagen

A private equity consortium led by Nordic Capital and Permira has lowered the minimum shareholder acceptance threshold for its takeover offer for Danish vaccine maker Bavarian Nordic, as it struggles to win enough support for the deal.

  • Previous
  • 1
  • 2

Filings

Recent filings

FilingDate
Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline13 Dec 2019
Bavarian Nordic A/S - Articles of Association29 Nov 2019
Bavarian Nordic A/S – Report on the Results of the Extraordinary General Meeting, held November 27, 201927 Nov 2019
Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial Officer13 Nov 2019
Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine Regimen7 Nov 2019
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such7 Nov 2019
Bavarian Nordic Announces Interim Results for the First Nine Months of 20197 Nov 2019
Bavarian Nordic A/S – Notice Convening Extraordinary General Meeting 25 Oct 2019
Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKline21 Oct 2019
Bavarian Nordic Updates on Phase 2 Study of CV301 in Bladder Cancer 18 Oct 2019
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine 8 Oct 2019
Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults24 Sept 2019
  • Previous
  • 1
  • More pages
  • 24
Search
Company
BAVARIAN NORDIC
BAVA.CONASDAQ Copenhagen
Website: Unavailable
Coverage
14
  • 3
  • Next
  • 25
  • 26
  • More pages
  • 78
  • Next
  • Filings
    927